UBS Maintains Buy on Solventum, Raises Price Target to $101

Benzinga Newsdesk www.benzinga.com Positive 79.3%

Neg 0% Neu 0% Pos 79.3%

UBS analyst Kevin Caliendo maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $95 to $101.

Comments

No comments yet. Be the first!